Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | ACP1 | P24666 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.50 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.50 |
| ▸ | RAD52 | P43351 | 3/20 | 0.47 |
| ▸ | PDE5A | O76074 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 4/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 2/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1289384 | 0.93 | POLB (0.66) | POLBSLC2A1ACP1ALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL4512327 | 0.92 | POLB (0.68) | POLBSLC2A1ACP1ALDH1A1MAPK1 | |
| SCHEMBL1289393 | 0.91 | POLB (0.52) | POLBSLC2A1ACP1ALDH1A1MAPK1 | |
| SCHEMBL1289430 | 0.89 | ALDH1A1 (0.65) | POLBSLC2A1ACP1ALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL4507915 | 0.88 | ALDH1A1 (0.67) | POLBSLC2A1ACP1ALDH1A1MAPK1 | |
| SCHEMBL12473363 | 0.85 | ALDH1A1 (0.60) | POLBSLC2A1ACP1ALDH1A1MAPK1 | |
| SCHEMBL4498537 | 0.85 | PDE5A (0.58) | POLBACP1ALDH1A1MAPK1RAD52 | |
| Hydrochloric Acid SCHEMBL4500478 | 0.84 | ALDH1A1 (0.62) | POLBSLC2A1ACP1ALDH1A1MAPK1 | |
| SCHEMBL1289433 | 0.84 | TLR9 (0.62) | POLBACP1ALDH1A1MAPK1RAD52 | |
| SCHEMBL1289520 | 0.79 | FLT3 (0.53) | POLBSLC2A1ALDH1A1MAPK1CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | claimed |
| WO-2012046207-A1 | ANTI-PARASITIC SUBSTITUTED RING FUSED AZINE COMPOUNDS | PARACO TECHNOLOGY LIMITED (NZ) | 2012-04-12 | — | — | WO | disclosed |
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | TP53, AZI2, MCL1 | POLB 3856/4885SLC2A1 3897/4885ACP1 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.